author-photo

Osamu Kondoh

Chugai Pharmaceutical Co.

25

Papers

697

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Anti-VEGF antibody protects against alveolar exudate leakage caused by vascular hyperpermeability, resulting in mitigation of pneumonitis induced by immunotherapy.

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab.

2021 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (1)
PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion.

2021 Clinical & Experimental Metastasis
Show All
- Source
- Cite
- Save
Citations (0)
Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model

2019 Clinical & Experimental Metastasis
Show All
- Source
- Cite
- Save
Citations (11)
Abstract 773: Alectinib shows potent antitumor activity against both ALK- and RET-rearranged non-small cell lung cancers

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

2014 Cancer Letters
Show All
- Source
- Cite
- Save
Citations (155)
Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer

2014 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (120)
Abstract 754: Selective ALK inhibitor alectinib (CH5424802/RO5424802) with potent antitumor activity in models of crizotinib resistance, including intracranial metastases

2014 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

2014 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (171)
Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer

2013 Cancer Science
Show All
- Source
- Cite
- Save
Citations (27)